Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

Serena P.H. Mao, Minji Park, Ramon M. Cabrera, John R. Christin, George S. Karagiannis, Maja H. Oktay, Dietmar M.W. Zaiss, Scott I. Abrams, Wenjun Guo, John S. Condeelis, Paraic A. Kenny, Jeffrey E. Segall

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. Methods: We crossed AREG-null (AREG-/-) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT). We evaluated tumor growth, cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG, Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors. Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG-/- mice than in AREG+/+ mice. Quantification of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG-/- mammary glands showed fewer K14+ cells and a thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG, epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG-/- PyMT tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas have lower AREG expression than luminal B invasive ductal carcinomas. Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary breast cancer in both the MMTV-PyMT model and human breast cancer.

Original languageEnglish (US)
Article number131
JournalBreast Cancer Research
Volume20
Issue number1
DOIs
StatePublished - Oct 26 2018

Fingerprint

Carcinogenesis
Breast
Breast Neoplasms
Health
Growth
Amphiregulin
Coculture Techniques
Keratin-14
Growth Disorders
Keratin-8
Neoplasms
Ductal Carcinoma
Atlases
Papillary Carcinoma
Fibroblast Growth Factor 2
Human Mammary Glands
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Estrogen Receptors
Flow Cytometry

Keywords

  • Amphiregulin
  • Breast cancer
  • Mammary ductal development
  • MMTV-PyMT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. / Mao, Serena P.H.; Park, Minji; Cabrera, Ramon M.; Christin, John R.; Karagiannis, George S.; Oktay, Maja H.; Zaiss, Dietmar M.W.; Abrams, Scott I.; Guo, Wenjun; Condeelis, John S.; Kenny, Paraic A.; Segall, Jeffrey E.

In: Breast Cancer Research, Vol. 20, No. 1, 131, 26.10.2018.

Research output: Contribution to journalArticle

Mao, Serena P.H. ; Park, Minji ; Cabrera, Ramon M. ; Christin, John R. ; Karagiannis, George S. ; Oktay, Maja H. ; Zaiss, Dietmar M.W. ; Abrams, Scott I. ; Guo, Wenjun ; Condeelis, John S. ; Kenny, Paraic A. ; Segall, Jeffrey E. / Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. In: Breast Cancer Research. 2018 ; Vol. 20, No. 1.
@article{5febc4100d8649aabdf9e6c8dba0ce41,
title = "Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis",
abstract = "Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. Methods: We crossed AREG-null (AREG-/-) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT). We evaluated tumor growth, cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG, Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors. Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG-/- mice than in AREG+/+ mice. Quantification of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG-/- mammary glands showed fewer K14+ cells and a thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG, epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG-/- PyMT tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas have lower AREG expression than luminal B invasive ductal carcinomas. Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary breast cancer in both the MMTV-PyMT model and human breast cancer.",
keywords = "Amphiregulin, Breast cancer, Mammary ductal development, MMTV-PyMT",
author = "Mao, {Serena P.H.} and Minji Park and Cabrera, {Ramon M.} and Christin, {John R.} and Karagiannis, {George S.} and Oktay, {Maja H.} and Zaiss, {Dietmar M.W.} and Abrams, {Scott I.} and Wenjun Guo and Condeelis, {John S.} and Kenny, {Paraic A.} and Segall, {Jeffrey E.}",
year = "2018",
month = "10",
day = "26",
doi = "10.1186/s13058-018-1057-0",
language = "English (US)",
volume = "20",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

AU - Mao, Serena P.H.

AU - Park, Minji

AU - Cabrera, Ramon M.

AU - Christin, John R.

AU - Karagiannis, George S.

AU - Oktay, Maja H.

AU - Zaiss, Dietmar M.W.

AU - Abrams, Scott I.

AU - Guo, Wenjun

AU - Condeelis, John S.

AU - Kenny, Paraic A.

AU - Segall, Jeffrey E.

PY - 2018/10/26

Y1 - 2018/10/26

N2 - Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. Methods: We crossed AREG-null (AREG-/-) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT). We evaluated tumor growth, cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG, Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors. Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG-/- mice than in AREG+/+ mice. Quantification of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG-/- mammary glands showed fewer K14+ cells and a thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG, epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG-/- PyMT tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas have lower AREG expression than luminal B invasive ductal carcinomas. Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary breast cancer in both the MMTV-PyMT model and human breast cancer.

AB - Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. Methods: We crossed AREG-null (AREG-/-) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT). We evaluated tumor growth, cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG, Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors. Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG-/- mice than in AREG+/+ mice. Quantification of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG-/- mammary glands showed fewer K14+ cells and a thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG, epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG-/- PyMT tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas have lower AREG expression than luminal B invasive ductal carcinomas. Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary breast cancer in both the MMTV-PyMT model and human breast cancer.

KW - Amphiregulin

KW - Breast cancer

KW - Mammary ductal development

KW - MMTV-PyMT

UR - http://www.scopus.com/inward/record.url?scp=85055614066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055614066&partnerID=8YFLogxK

U2 - 10.1186/s13058-018-1057-0

DO - 10.1186/s13058-018-1057-0

M3 - Article

C2 - 30367629

AN - SCOPUS:85055614066

VL - 20

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 131

ER -